An allogeneic cell therapy for the treatment of Osteochondral Lesions (LOCs) that consists of a subpopulation of umbilical cord tissue mesenchymal cells (UC-MSCs) incorporated within a Platelet Poor Plasma (PPP) biomatrix.

  • Cellistem®Hydrogel therapy designed to be infiltrated arthroscopically after debridement of the lesion and the microfracture procedure (MF)


  • Validation through a prospective, multicenter, double-blind clinical study in 70 patients with symptomatic Osteochondral Talus Lesion, which seeks to compare the effectiveness of traditional debridement and microfracture treatment versus additionally adding mPPP + UC-MSCs


Technology Readiness Level (TRL)